Stock Market Today, March 17: Blue Owl Capital Rises Though Private Credit Fears Linger

Blue Owl Capital closed at $9.15, up 4.45% with volume 41.8M shares (~57% above its 3-month average of 26.6M). The stock is down over 50% in the past year and ~15% since its 2020 IPO, reflecting private-credit fears, a software-heavy exposure and recent redemption restrictions on certain funds. Potential positive contributors include broader alternative-asset peer strength, a $550M loan to Scholar Rock and an Oppenheimer 'outperform' reiteration, but investor caution persists amid ongoing stress in private credit.

Analysis

Blue Owl’s repricing is less a pure equity story than a credit-structure story: concentrated, covenant-light loans to high-growth software and selective biopharma credits amplify mark-to-model volatility and make NAV math hinge on forward fundraising and redemption behavior. That elevates second-order pressure on warehousing banks and CLO warehouses — a pullback in committed financing would slow new deal flow and force fee amortization to shift from new origination to asset-management fees, benefiting managers with larger fee-for-service streams.

Near-term catalysts are bifurcated: sentiment and flows drive days-to-weeks moves (short covering, sector ETF rotation), but realizations of credit loss or covenant resets play out over quarters. Key reversal triggers include (a) a visible uptick in private-credit default/covenant breach notifications within 3–9 months, (b) a demonstrable reopening of redemption windows or liquidity facilities from prime banks, or (c) a Fed pivot that re-rates spread assets and reduces funding stress.

Contrarian angle — the market is pricing a high-probability systemic loss across a heterogeneous asset class. Large, diversified alternative managers with broader origination channels and bank-like funding (e.g., BX, ARES) can both earn wider new-paper yields and cross-fund stressed vehicles, so a partial mean-reversion in relative performance is plausible over 6–12 months. That makes carefully sized volatility-defined trades attractive: asymmetry favors buying time and buying protection rather than outright directional leverage on NAVs.

Key Decisions for Investors

• Pair trade (3–6 months): Short OWL / Long BX equal notional. Target 20–30% relative outperformance for BX if private-credit stress persists; hard stop if OWL outperforms BX by 10% to limit sector mean-reversion risk. Rationale: BX’s more diversified fee and funding mix should compress on stress slower than a concentrated credit originator.
• Defined-risk hedge (1–3 months): Buy OWL 6-month put spread (buy 1x 15% OTM put, sell 1x 30% OTM put) sized at <1% portfolio risk. Reward: captures near-term downside from redemption or headline credit events while capping premium outlay; risk: limited to paid premium if sentiment stabilizes.
• Contrarian asymmetric long (9–12 months): Buy OWL 12-month call spread (buy 1x 50% OTM call, sell 1x 80% OTM call) as a low-cost recovery ticket — allocate capital equal to expected loss on short exposures. Rationale: if marks normalize and fundraising resumes, upside is multi-bagger relative to premium paid; downside limited to premium.
• Relative-value long (6–12 months): Overweight ARES (ARES) vs OWL — tactical long ARES for total-return capture of 20–35% if private-credit spreads re-tighten. Size exposure with 6–8% portfolio allocation and use a 15% trailing stop; risk: broader contagion that compresses asset-manager multiples across the board.